Philip Gioia, President, Nordic Pharma, provides a company update at the recent Eyecelerator meeting in Chicago: https://bit.ly/4gtWY23
Eyewire+
Book and Periodical Publishing
Wayne, PA 11,025 followers
Eyewire+ is devoted to keeping readers updated with the latest information in the ophthalmic and eye care fields.
About us
Eyewire+ keeps readers updated with the latest in the ophthalmic field, featuring breaking news from press releases, medical journals, vision publications, videos, and other news sources. EyewireTV is the only weekly news broadcast devoted entirely to the ophthalmic industry.
- Website
-
https://eyewire.news/
External link for Eyewire+
- Industry
- Book and Periodical Publishing
- Company size
- 11-50 employees
- Headquarters
- Wayne, PA
- Specialties
- eye care, optometry, opthalmology, ophthalmics, doctors, medicine, med students, media, publishing, and news
Updates
-
Celltrion Inc announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted positive opinions and recommended marketing authorizations for three biosimilar candidates, including Eydenzelt (CT-P42, aflibercept): https://bit.ly/4gKpg88
-
Bausch + Lomb makes an acquisition to expand its glaucoma surgical offerings; Roche gets a major approval in Europe for Vabysmo; and EssilorLuxottica buys a maker of noninvasive ophthalmic medical devices: https://bit.ly/3DyuOUT
-
Kate Hunt, Chief Commercial Officer, Nova Eye Medical, provides a company update at the recent Eyecelerator meeting in Chicago: https://bit.ly/403nNTZ
-
-
Aurion Biotech announced topline data from its phase 1/2 clinical trial (CLARA) of AURN001, an allogeneic cell therapy product candidate for the treatment of corneal edema secondary to corneal endothelial dysfunction: https://bit.ly/4fkEdwx
Aurion Announces Positive Topline Data for Phase 1/2 Trial of Allogeneic Cell Therapy for Corneal Edema Secondary to Corneal Endothelial Dysfunction - Eyewire+
eyewire.news
-
Nick Ruth, Chief Commercial Officer, Sydnexis, provides a company update at the recent Eyecelerator meeting in Chicago: https://bit.ly/4iAWNU1
-
-
The European Medicines Agency (EMA) has approved Roche's Vabysmo (faricimab) 6.0 mg single-dose prefilled syringe (PFS) for use in the treatment of wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO): https://bit.ly/4galG7v
Vabysmo Prefilled Syringe (PFS) Approved in the EU - Eyewire+
eyewire.news
-
👁️ Welcome to the Eyewire+ Weekly Digest! The must-read hub for ophthalmology and optometry—delivering fresh podcasts, trending stories, and expert insights across every subspecialty. Stay in the know—explore now!
Trending Stories on Eyewire+
Eyewire+ on LinkedIn
-
Atsena Therapeutics announced dosing has been completed in Part A of the LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS): https://bit.ly/3PjnVd3
Atsena Therapeutics Completes Dosing in Part A of Phase 1/2 Trial Evaluating Gene Therapy ATSN-201 to Treat X-linked Retinoschisis - Eyewire+
eyewire.news
-
Tenpoint Therapeutics Ltd and Visus Therapeutics announced the completion of their merger. Henric Bjarke has been appointed Chief Executive Officer of the newly merged company: https://bit.ly/49zRvnA
Tenpoint and Visus Complete Merger - Eyewire+
eyewire.news